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Abstract: Perinatal arterial ischemic stroke (PAIS) is one of the frequent causes of 
mortality and morbidity, but its etiology remains unclear. COL4A1 and COL4A2 
mutations are monogenetic causes of weakness of the basement vascular membranes 
resulting in cerebral small-vessel disease, cerebral hemorrhage, and porencephaly. We 
hypothesized that variations in the COL4A1 and COL4A2 genes cause PAIS and 
performed mutation screening of these genes in 17 PAIS patients by whole-exome 
sequencing. Clinical, demographic, and laboratory data of the 17 PAIS patients were 
obtained by evaluating hospital files retrospectively. Patients included in the study were 
invited to the clinic for COL4A1 and COL4A2 mutation analysis. Results: The patient 
group consisted of 13 females (76.5%) and four males (23.5%) with a mean age of 
107.4 ± 11.5 months. Maternal/fetal and prothrombotic risk factors identified in 52.9% 
and 94.1% of the patients, respectively. Whole-exome sequencing analysis did not 
reveal COL4A1 and COL4A2 pathological mutations in any of the patients.  Although we 
did not find an association between PAIS and COL4A1 and COL4A2 variations, we 
believe that new studies with larger patient populations may reveal such a relationship. 
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INTRODUCTION 
 Perinatal ischemic stroke is one of the frequent causes of morbidity and severe 
long-term neurologic and cognitive deficits, including cerebral palsy, epilepsy, 
neurodevelopmental disabilities, behavioral disorders, and impaired vision and 
language function1. It defined as “a group of heterogeneous conditions involving focal 
disruption of cerebral blood flow secondary to arterial or venous thrombosis or 
embolization between the 20th week of fetal life through the 28th postnatal day”, and 
the diagnosis should always be confirmed by neuroimaging or by neuropathological 
investigations2. The two main categories are periventricular arterial ischemic stroke 
(PAIS) and cerebral sinovenous thrombosis. The incidence of PAIS ranges from 1 in 
2300 to 5000 births3,4. The etiology of PAIS has not been fully established but 
considered to be the result of multifactorial risk factors during pregnancy and delivery5-8. 
Tropical Health and Medical Research  
Vol.2, No.1, March 2020, pp.18-25 
ISSN (Online) : 2684-740X 
Journal homepage:medlabtecnojournal.com 
 
P a g e  | 19 
 
 
 
 The basement membrane (BM), including the vascular BM, is an extracellular 
matrix associated with overlying cells that is important for proper tissue development, 
stability, and physiology9. Type IV collagen, which is a significant protein expressed in 
many tissues, including the vascular endothelia, is critical for the formation of stable 
BMs during embryonic development10,11. α1(IV) and α6(IV), encoded by COL4A1 to 
COL4A6, respectively, are considered to be the classical type IV collagen alpha 
chains12. Dominant missense mutations in COL4A1 and COL4A2 are associated with 
multisystemic disorders, including intracerebral hemorrhage, porencephaly, 
nephropathy, ocular malformation, and myopathy13,14. Van der Knaap et al.15. reported 
focal disruptions and a significant increase in the thickness of the vascular BM of human 
skin capillaries due to COL4A1 and COL4A2 mutations. It has suggested that focal 
disturbances of the vascular BM can predispose to bleeding. 
 In contrast, the swelling of vascular endothelial cells and the increased thickness 
of the BM can lead to narrowing of vessels and thus predispose to ischemic damage. 
Previous studies are generally about perinatal hemorrhage and multisystemic 
involvement of COL4A1 and COL4A2 mutations. Our primary aim was to identify 
possible relations with COL4A1 and COL4A2 mutations with PAIS. 
 We hypothesized that COL4A1 and COL4A2 mutations cause PAIS, and herein, 
we report on the study of 17 PAIS patients who examined for COL4A1 and 
COL4A2 mutations by whole-exome sequencing. 
 
MATERIALS AND METHODS 
 Seventeen patients diagnosed with PAIS and followed-up at the Eskisehir 
Osmangazi University Hospital, Department of Pediatric Neurology, between January 
2011 and September 2016 were the participants of this study. The Clinical Research 
Ethics Committee approved the study protocol of the Eskisehir Osmangazi University 
School of Medicine, and the study conducted according to the Declaration of Helsinki. I 
have written informed consent obtained from the parents of each patient. Clinical, 
demographic, neuroimaging (cranial magnetic resonance imaging (MRI), and laboratory 
data of the PAIS patients were obtained by evaluating hospital files retrospectively. 
 The diagnosis of PAIS based on clinical features, neurological examination, and 
cranial MRI findings. Inclusion criteria were PAIS confirmed using MRI and a follow-up 
period of more than six months. Patients who had a congenital cerebral anomaly, 
cerebrovascular disorder, brain tumor, sequel of hypoxic-ischemic encephalopathy, 
cortical dysplasia, central nervous system infection, preterm birth, or trauma excluded. 
 All patients’ prenatal and natal history, as well as maternal risk factors, were 
obtained using a standard form. Prothrombotic risk factors such as factor V Leiden, 
methylenetetrahydrofolate reductase (MTHFR) (C677T and A1298C), and 
prothrombin G20210A mutations; homocysteine, protein C/S, lipoprotein (a), 
antithrombin III (ATIII), and factor VIII levels; and the presence of anticardiolipin 
antibodies and lupus anticoagulant obtained from reviews of the medical histories. 
 
Whole-exome sequencing for COL4A1 and COL4A2 mutations 
 Patients included in the study were invited to the clinic for COL4A1 and 
COL4A2 mutation analysis. Written informed consent obtained from both parents. 
Genomic DNA from the patients captured using the SureSelectXT Human All Exon v5 
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Kit (Agilent Technologies, Santa Clara, CA, USA) and sequenced with six samples per 
lane on an Illumina HiSeq 2000 (Illumina, San Diego, CA, USA) with 101-bp paired-end 
reads. Image analysis and base calling performed by sequence control software real-
time analysis and CASAVA software v1.8 (Illumina). Exome data processing, variant  
calling, and variant  annotation performed as previously described16-19. 
 
RESULT AND DISCUSSION 
 A total of 22 patients were excluded because of hypoxic-ischemic 
encephalopathy (10), periventricular leukomalacia (7), malformation (3), and metabolic 
disorders (2), leaving a study population of 17 children. 
 The patient group consisted of 13 females (76.5%) and four males (23.5%) with a 
mean age of 107.4 ± 11.5 months. The average duration of follow-up was 46 months 
(range: 9–122). None of the patients had a positive family history of stroke. All patients 
had delivered by cesarean section, and there were no reported placental abnormalities. 
All births occurred at term, and the average birth weight was 3100g (1900–4700g). Six 
parents were involved in consanguineous marriages. All of the patients’ 
echocardiography results were normal. Maternal/fetal risk factors were associated with 
52.9% of patients (intrauterine growth retardation (IUGR) (35.3%), twin pregnancy 
(5.9%), and abnormal vaginal bleeding (11.7%)). Epilepsy (70.6%), mild/severe 
intellectual disability (64.7%), behavioral disorders (17.6%), unilateral spastic cerebral 
palsy (100%), and congenital hemiplegia (100%: 10 right and seven left) found in the 
patients. 
 Prothrombotic risk factors detected in 94.1% of the patients. MTHFR mutations 
detected in 76.5% of the patients, with the A1298C heterozygous carrier state present in 
7 patients, the A1298C homozygous carrier state in 3, the C677T heterozygous carrier 
state in 2, the C677T homozygous carrier state in 2, and the combined 
(C677T+A1298C) mutation carrier state in 1. Factor V Leiden heterozygous mutation 
found in 1 patient. Combined MTHFR and factor V Leiden mutations found in 2 patients. 
In all patients, lupus anticoagulant was negative, and factor VIII levels were within 
normal limits. Prothrombin G20210A mutation increased levels of anticardiolipin 
antibodies, protein S deficiency, hyperhomocysteinemia, protein C deficiency, and 
antithrombin III deficiency not detected in any of the patients. We conducted a whole-
exome sequencing analysis for COL4A1 and COL4A2 mutations in the 17 PAIS 
patients, which showed no pathological mutations in either gene in any of the patients 
(Table 1). 
 PAIS is one of the most typical forms of pediatric stroke and 17 times greater 
than the incidence of AIS in children20. Approximately 60% of perinatal strokes result in 
neurological deficits, including cerebral palsy, neurocognitive deficits, language 
impairment, behavioral disorders, and epilepsy, and emerging deficits during the school 
years such as learning disabilities21. In our study, all 17 patients had congenital 
hemiplegia (unilateral spastic cerebral palsy), 70.6% had epilepsy, 64.7% had an 
intellectual disability, and 17.6% had behavioral disorders. However, the 
pathophysiology and risk factors of PAIS remain mostly unclear. Maternal risk factors 
include infertility, preeclampsia, chorioamnionitis, placental vasculopathy, coagulation 
disorders, and cocaine abuse; fetal risk factors include growth restriction, intrauterine 
asphyxia, heart diseases, infections, congenital vascular anomalies, dehydration, and 
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traumatic delivery; and there are also prothrombotic risk factors. However, the role of 
these factors on the occurrence of PAIS remains unclear22-24. 
 In our study, maternal/fetal risk factors were present for 52.9% of patients, 
including pregnancy with twins, abnormal vaginal bleeding, and IUGR. Stroke more 
frequently affects the left hemisphere and often involves the middle cerebral artery 
(MCA) territory25. In our study, 10(7) of 17 patients had left MCA stroke. 
 
Table 1: Clinical and Radiological Characteristics and Risk Factors of Patient 
 
Patient 
no 
Sex/ 
Age 
(mo) 
Side of 
hempl
egia 
Clinical 
features 
MRI findings 
(stroke 
localization) 
Risk factors COL4A1/
COL4A2 
mutation 
1 38/M R Epilepsy, 
intellectuel 
disabilty  
L. MCA MTHFR 
A1298C 
Het.+FVL Het. 
Negative 
2 42/F L Intellectuel 
disabilty 
R. MCA MTHFR 
A1298C Het. 
Negative 
3 50/F L Intellectuel 
disabilty 
L. MCA MTHFR 
A1298C Hom., 
IUGR 
Negative 
4 56/M L Epilepsy, 
intellectuel 
disabilty  
R. MCA MTHFR 
C677T Hom., 
IUGR 
Negative 
5 64/M R Intellectuel 
disabilty 
L. MCA MTHFR 
A1298C Hom. 
Negative 
6 72/F R Epilepsy L. MCA MTHFR 
A1298C Het. 
Negative 
7 96/F R Epilepsy, 
intellectuel 
disabilty 
L. MCA MTHFR 
A1298C Hom., 
Twin dizygotic, 
IUGR 
Negative 
8 96/F L Intellectuel 
disabilty  
R. MCA MTHFR 
A1298C Het. 
Negative 
9 120/F R Epilepsy, 
intellectuel 
disabilty  
L. MCA FVL Het., 
IUGR 
Negative 
10 120/F R Epilepsy, 
intellectuel 
disabilty  
L. MCA MTHFR 
A1298C Het. 
Negative 
11 132/
M 
L Epilepsy, 
intellectuel 
disabilty  
R. MCA MTHFR 
A1298C 
Het.+FVL Het. 
Negative 
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Patient 
no 
Sex/ 
Age 
(mo) 
Side of 
hempl
egia 
Clinical 
features 
MRI findings 
(stroke 
localization) 
Risk factors COL4A1/
COL4A2 
mutation 
12 132/F R Epilepsy  L. MCA MTHFR 
C677T Het., 
abnormal 
vaginal 
bleeding 
Negative 
13 136/F R Intellectuel 
disabilty 
L. MCA MTHFR C677 
Hom., IUGR 
Negative 
14 144/F R Epilespy L. MCA MTHFR 
A1298C Het. 
Negative 
 
 
15 166/F L Epilepsy R. MCA MTHFR 
C677T 
Het.,IUGR 
Negative 
16 175/F L Epilepsy, 
intellectuel 
disabilty  
R. MCA MTHFR 
C677T Het.+ 
MTHFR 
A1298C Het. 
Negative 
17 187/F R Epilepsy, 
intellectuel 
disabilty 
L. MCA Abnormal 
vaginal 
bleeding 
Negative 
Abbreviations: F:female, M:male, mo:months, R: right, L:left, MCA:middle cerebral 
artery, MTHFR: methylenetetrahydrofolate reductase, het:heterozygosity, 
hom:homozygosity, FVL: factor V Leiden; IUGR: intrauterin growth retardation 
 
 COL4A1 and COL4A2 genes located at chromosome 13q34. They encode the 
collagen chains a1(IV) and a2(IV), which constitute a significant component of the 
vascular BM26, COL4A1 variants that cause an autosomal dominant disorder affecting 
the structural integrity of the BM resulting in perinatal cerebral hemorrhages and 
porencephaly first reported in 200527. In 2012, it stated that mutations in 
the COL4A2 gene at the same chromosomal locus caused a similar phenotype of 
cerebral small-vessel disease (SVD) manifesting as intracerebral hemorrhage (ICH), 
early-onset porencephaly, and nephropathy28,29. In addition to cerebrovascular 
disease, COL4A1 and COL4A2 mutations confirmed to cause ocular, renal, and 
muscular disorders. Ophthalmologic findings including bilateral tortuosity of the second- 
and third-order arteries, hemorrhagic lesions, and the Axenfelde Rieger anomaly 
characterized by microcornea, congenital, or juvenile cataracts, increased intraocular 
pressure, iris hypoplasia, retinal detachment, and optic nerve excavation9,14,30,31. Renal 
involvement manifests as hematuria and renal cysts9,30. Muscle cramps involving a 
variety of muscles have been reported, with associated persistent elevation of serum 
creatine kinase concentrations (HANAC syndrome)31. 
 Neurological features COL4A1 and COL4A2 mutations include porencephaly, 
SVD, ICH, ischemic strokes, white matter hyperintensity (WMH), dilated perivascular 
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spaces, intracranial aneurysms, seizures, congenital hemiplegia, myopathy, migraine, 
cognitive impairment, and dementia15,26,32,33. In addition to pre- and perinatal 
hemorrhages, COL4A1, and COL4A2 mutations also cause sporadic and recurrent ICH 
in young and old patients. Van der Knaap et al.15. reported 
that COL4A1 and COL4A2 mutations might cause an ischemic stroke. Genetic studies 
about ischemic stroke and hemorrhagic strokes have generally been pursued 
separately and have focused on different etiological causes. Rannikmäe et al.34. 
conducted a meta-analysis on COL4A2 mutations associated with ischemic and 
hemorrhagic stroke and found that the same genetic signal is associated with clinically 
evident sporadic ischemic and hemorrhagic stroke. Another study found 
that COL4A1 and COL4A2 cause deep ICH and symptomatic cerebral SVD 
phenotypes, which is suggestive of associations in the same direction for these single 
nucleotide polymorphisms with other cerebral SVD phenotypes: lacunar ischemic stroke 
and WMH in ischemic stroke cases35. According to these studies, we hypothesized 
that COL4A1 and COL4A2 mutations cause both perinatal hemorrhagic stroke and 
PAIS. 
 To the best of our knowledge, this is the first study to attempt to 
link COL4A1/COL4A2 mutations and PAIS. However, we could not find an association 
between them. Our principal study limitation is the small patient population. Although 
PAIS is a significant cause of morbidity and mortality, its pathophysiology is not fully 
understood. COL4A1 and COL4A2 mutations are still a potential risk factor for PAIS. 
We believe that new studies with a large patient population may allow us to understand 
whether there is a relationship between COL4A1 and COL4A2 mutations and PAIS. 
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